{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04965090","nct_id":"NCT04965090","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04965090. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh \\<80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.","label":"Patients with parenchymal brain metastases","type":"EXPERIMENTAL"},{"description":"All patients in both cohorts will receive both oral lazertinib and amivantamab by intravenous injection (IV). Lazertinib dosing will start at 240 mg daily. For patients who weigh \\<80 kg, on C1D1 amivantamab 350 mg will be given IV via peripheral line for C1D1, D2 and D8, with 700 mg IV given on C1D2. For all other treatments, amivantamab 1050 mg IV will be given. For patients who weigh ≥ 80 kg, on C1D1 350mg IV amivantamab will be given and 1050 mg IV on C1D2, with 1400 mg IV given for all.","label":"Patients with leptomeningeal (LM) disease with or without parenchymal brain metastases","type":"EXPERIMENTAL"}],"collaborators":["Janssen Scientific Affairs, LLC"],"completion_date":{"date":"2025-12-15","type":"ACTUAL"},"conditions":["Metastatic Non Small Cell Lung Cancer","Recurrent Non Small Cell Lung Cancer"],"enrollment":{"count":43,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Amivantamab","otherNames":[],"type":"DRUG"},{"name":"Lazertinib","otherNames":[],"type":"DRUG"}],"last_update":"2025-12-18","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-12-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"CNS overall response rate (ORR) (Cohort 1)","timeFrame":"2 years"},{"measure":"measure CNS overall response rate (ORR) (Cohort 2)","timeFrame":"2 years"}],"references":[{"citation":"Chen MF, Lee JJ, Choudhury NJ, Hui AB, Jeng MY, Zheng J, Aly RG, Sielski N, Ahn L, Pupo A, Nesselbush MC, Jabara I, Wilcox JA, Santomasso BD, Lin AL, Schaff L, Chaft JE, Riely GJ, Kris MG, Arfe A, Yang SR, Young RJ, Diehn M, Boire A, Yu HA. Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2026 Mar;21(3):103505. doi: 10.1016/j.jtho.2025.10.012. Epub 2025 Oct 23.","pmid":"41139066","type":"DERIVED"}],"start_date":{"date":"2021-09-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04965090"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04965090"}